Nathan Sweeney is Director of Rentschler Biopharma’s ATMP Technical Strategy. His role relies on sound scientific understanding of advanced therapies to direct strategy and scope for internal and client projects.  Previously, Nathan held a technical leadership and client-facing role at the Cell and Gene Therapy Catapult where he managed a large multi-disciplinary team and led process and analytical development projects focussed on innovations in viral vector manufacturing. Prior to that, he worked at GSK in cell and gene therapy where his responsibilities included team leadership on viral vector and stable cell line development in addition to being a matrix leader for CMC strategy and development activities to progress a lentiviral vector from discovery phase to clinic as part of a CAR-T therapy. He supported cell and gene therapy assets across all preclinical and clinical phases. Nathan is a lead author on multiple peer-reviewed scientific publications and an inventor on 3 patent applications related to cell and gene therapy. He holds a Ph.D. in virology and an MRes in the molecular and cellular basis of infection from Imperial College London, along with a BSc in Biological Sciences with a specialization in virology from the University of Warwick.